Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The International Council for Harmonisation (ICH) held its Assembly meeting on 13–14 May 2025 in Madrid, Spain, alongside 11 Working Groups and prior meetings of the Management and MedDRA Steering Committees.

Membership Updates
ICH welcomed three new Observers: DINAVISA (Paraguay), MOH (Kuwait), and SRS (El Salvador), bringing the total to 23 Members and 41 Observers. Mr. Daisuke Koga (MHLW/PMDA, Japan) was elected as the new Vice-Chair of the ICH Management Committee.

New Harmonisation Topics
Four new topics were adopted for future guideline development:

  • Use of Real-World Evidence for regulatory decisions
  • Utility of Comparative Efficacy Studies in biosimilar development
  • Natural History Studies and Registry Data in rare disease drug development
  • Comparability of ATMPs following manufacturing changes (Annex to ICH Q5E)

Guideline Progress and Milestones
The Assembly acknowledged progress on several guidelines:

  • Finalised (Step 4):
    • ICH E6(R3): Revised “Good Clinical Practice” guideline adopted in January 2025
  • New Drafts Endorsed (Step 2):
    • ICH M4Q(R2): Updated Common Technical Document (CTD) for pharmaceutical registration.
    • ICH E21: Inclusion of pregnant and breastfeeding individuals in clinical trials.
    • ICH Q1: Stability testing of drug substances and products.
    • ICH M13B: Biowaivers for additional strengths of immediate-release solid oral dosage forms in bioequivalence studies
    • ICH M11: Updated Technical Specification for the electronic protocol standard (CESHARP).
    • ICH M7 Addendum: Framework for assessment and control of DNA-reactive impurities, including nitrosamines.

MedDRA Updates
New MedDRA Steering Committee appointments: NMPA (China), SFDA (Saudi Arabia), and IFPMA (Standing Observer). MedDRA is now used by over 9,000 organizations in 141 countries and available in 24 languages, including Icelandic. The MedDRA LMS, launched in early 2025, offers structured online training.

Next Meeting
The next ICH Assembly will take place on 18–19 November 2025 in Singapore.


Source:

ICH: Press Release


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
Previous
Next